Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 25Breast Neoplasms 14Neoplasms 12Myelodysplastic Syndromes 12Prostatic Neoplasms 10Multiple Myeloma 8Lung Neoplasms 7Stomach Neoplasms 6Sarcoma 6Ovarian Neoplasms 5Leukemia, Myelomonocytic, Chronic 5Recurrence 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Head and Neck Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumor 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Solid Tumor 3Small Cell Lung Carcinoma 3Pain 3Mucositis 3Lymphoma, T-Cell, Peripheral 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Carcinoma, Hepatocellular 3Stomatitis 2Skin Neoplasms 2

Interventions

Prednisone 5enzalutamide 4cabazitaxel 4Docetaxel 3XRP6258 2Abiraterone Acetate 2sipuleucel-T 1rucaparib 1olaparib 1apalutamide 1Zuclomiphene 1Standard of Care 1Prednisolone 1Lenograstim 1LY3023414 1Injections 1Hematologic Tests 1Granulocyte Colony-Stimulating Factor 1Abituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Prostate Cancer Metastatic × Injections × Clear all
NCT04028388 2024-04-17

ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

Modra Pharmaceuticals

Phase 2 Completed
135 enrolled 29 charts
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡